Abstract Library

#4588 Spatial transcriptomics identifies Wnt signalling in multifocal ileal neuroendocrine tumours

Introduction: Ileal neuroendocrine tumours (i-NETs) often present with multiple primary tumours (>30-40%). Recent studies showed no shared somatic mutations in multiple primary tumours, highlighting the need to examine the tumour microenvironment in tumorigenesis. The Wnt signalling pathway is crucial for organ stem cell regulation. While the Wnt/β-catenin pathway influences prostate and pancreatic NET/Cs, its role in i-NETs remains unclear.

Conference:

Presenting Author:

Authors: Yogo A, Akanuma N, Kim G, Thirlwell C, Mäkinen N,

Keywords: Wnt Signalling, Spatial Transcriptomics,

#4521 [18F]FDG (FDG) PET/CT metrics as prognostic biomarkers in the AGITG NABNEC trial

Introduction: NABNEC was a prospective phase II trial investigating carboplatin/nab-paclitaxel in patients with advanced Grade 3 NENs (NCT02215447).

Conference:

Presenting Author: Kong G

Authors: Kong G, Ayati N, Brown C, Siu D, Mak W,

Keywords: Prognostic marker, prospective trial, chemotherapy, PET imaging, FDG, metabolic tumour volume, suv,

#4181 High prevalence of deficiencies in fat-soluble vitamins, minerals and trace elements but no relation with malnutrition in patients with gastroenteropancreatic neuroendocrine tumors using somatostatin analogues

Introduction: Since 2019 the Global Leadership Into Malnutrition (GLIM) criteria exist for diagnosing malnutrition. Patients (pts) with gastoenteropancreatic (GEP) neuroendocrine tumors (NETs) treated with somatostatin analogues (SSAs) are at risk of malnutrition. Deficiencies in fat-soluble vitamins, minerals and trace elements (micronutrients) are not part of the GLIM criteria but frequently reported in pts with GEP-NETs treated with SSAs.

Conference:

Presenting Author: Clement D

Authors: Clement D, van Leerdam M, Tesselaar M, Cananea E, Martin W,

Keywords: gastroenteropancreatic neuroendocrine tumor, somatostatin analogue, malnutrition, sarcopenia, survival,

#3845 The lungNENomics project – A comprehensive multidisciplinary characterisation of pulmonary carcinoids

Introduction: Lung neuroendocrine tumors (LNETs) are subdivided into low-grade (typical) and intermediate-grade (atypical) carcinoids, at higher risk of developing metastases. We have previously identified 3 LNETs molecular groups with different prognoses, as well as “supra-carcinoids” with molecular profiles of higher-grade neuroendocrine carcinomas. Despite promising results, there is still no consensus on their differential diagnosis and treatment and little is known about how some tumors evolve toward more aggressive phenotypes.

Conference:

Presenting Author:

Authors: Foll M, Sexton-Oates A, Mathian E, Alcala N, Mangiante L,

Keywords: lung carcinoid, deep learning, genomic, evolution, multi-omics, spatial analyses,

#1305 PRRT for Malignant Pheochromocytomas and Paragangliomas: The Singapore General Hospital Experience

Introduction: In recent years, the use of 177Lu-DOTATATE radioisotope therapy has been expanded to patients with metastatic pheochromocytomas and paragangliomas (PCC/PGL). Although this is not the standard of care, treatment options are limited for those with MIBG negative disease. Our centre has treated over 40 patients with NETS with PRRT since 2012.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Loh L, Lim D, Loke K, Ng D,

Keywords: PRRT, pheochromocytoma, paraganglioma,